Syna Therapeutics signs global deal on biosimilar LB-0702

Four years after it was established, Syna Therapeutics has just signed an exclusive license agreement with Indian drugmaker Intas Pharmaceuticals and its wholly-owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702 to treat pathologies in the field of hematology.

Set up in 2018, Syna Therapeutics is a joint venture owned by LeanBio and Spain’s Reig Jofre (BME: RJF), for the development of biopharmaceutical products in the field of biosimilars and innovative molecules.

According to the terms of the agreement, Syna Therapeutics will begin in 2023 the clinical trials for its biosimilar LB-07802. For its part, Intas, will cover the marketing costs. Intas currently has one of the largest sales, marketing, and distribution networks for biosimilars in the world, particularly to hospitals, with a presence in 85 countries.